Breaking News, Financial News

Financial Report: Charles River Labs 1Q

Early Discovery acquisitions contribute to growth

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Laboratories 1Q Revenues: $320.4 million (+7%) 1Q Earnings: $31.6 million (-3%) Comments: Research Models and Services (RMS) revenue was $120.0 million, down 9%, primarily due to the Genetically Engineered Models and Services (GEMS) business and lower sales of research models in Europe. Discovery and Safety Assessment (DSA) revenue was $140.0 million, driven primarily by the Early Discovery acquisitions, which contributed 23% to DSA revenue growth. Revenue for the Manufacturing ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters